BRIEF-SuperX AI Technology To Sell 3.3 Million Units At $12.08 Each In Private Placement - SEC Filing-February 2024-www.financetom.com

BRIEF-SuperX AI Technology To Sell 3.3 Million Units At $12.08 Each In Private Placement - SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-SuperX AI Technology To Sell 3.3 Million Units At $12.08 Each In Private Placement - SEC Filing

Oct 24, 2025 2:24 PM

Oct 24 (Reuters) - SuperX AI Technology Ltd ( SUPX ):

* SUPERX AI TECHNOLOGY LTD ( SUPX ): AGREED TO ISSUE, SELL IN

PRIVATE

PLACEMENT AGGREGATE OF 3.3 MILLION UNITS AT US$12.08/PURCHASER

UNIT - SEC FILING

* SUPERX AI TECHNOLOGY ( SUPX ): PROCEEDS TO CO EXPECTED TO BE ABOUT

$39.9

MILLION, WITH POTENTIAL TO INCREASE BY US$13.3 MILLION IF

WARRANTS EXERCISED

Source text:

Further company coverage:

Previous page： Scotiabank Previews Friday's GDP Data in Canada; Notes Early Bond Market Close Friday Next page： MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Scotiabank Previews Friday's GDP Data in Canada; Notes Early Bond Market Close Friday

Oct 2, 2024

08:20 AM EDT, 09/27/2024 (MT Newswires) -- Canada releases estimates for July gross domestic prodcut and flash August GDP at 8:30 a.m. ET Friday, said Scotiabank. The bank estimated 0.2% month-over-month seasonally adjusted growth, while consensus is at 0.1%. Statistics Canada had guided essentially unchanged on Aug. 30 which usually means -0.1% month over month to +0.1%. Data since then...

MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models

Oct 2, 2024

08:26 AM EDT, 09/27/2024 (MT Newswires) -- MIRA Pharmaceuticals ( MIRA ) said Friday that preclinical data showed its oral ketamine analog Ketamir-2 achieved a complete reversal of neuropathic pain in preclinical models. In preclinical studies, Ketamir-2 showed superior efficacy compared with ketamine, the company said, adding that it is on track to submit an investigational new drug application to...

Foraco Launches Normal Course Issuer Bid

Oct 2, 2024

08:26 AM EDT, 09/27/2024 (MT Newswires) -- Foraco International ( FRACF ) said Friday that it received TSX approval to launch a normal course issuer bid (NCIB). Under the NCIB, the drilling company can purchase up to 1 million shares or 1% of its issued and outstanding stock as of Sept. 17. Foraco ( FRACF ) said it intends to...

Bumble Shares Drop After Downgrade From KeyBanc

Oct 2, 2024

08:19 AM EDT, 09/27/2024 (MT Newswires) -- Bumble (BMBL) shares fell almost 3% in recent premarket trading Friday after KeyBanc downgraded the company's stock to sector weight. KeyBanc said Bumble's app data shows continued weakness, with global downloads remaining flat year-over-year and US downloads declining by double-digits. KeyBanc also noted that Bumble's recent app refresh, specifically the Opening Moves feature...